BioCryst Historical Income Statement

BCRX Stock

USD 7.50 0.01 0.13%

Historical analysis of BioCryst Pharmaceuticals income statement accounts such as Interest Expense of 113.7 M, Selling General Administrative of 209.1 M or Total Revenue of 348 M can show how well BioCryst Pharmaceuticals performed in making a profits. Evaluating BioCryst Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioCryst Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining BioCryst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioCryst Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

About BioCryst Income Statement Analysis

BioCryst Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioCryst Pharmaceuticals shareholders. The income statement also shows BioCryst investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BioCryst Pharmaceuticals Income Statement Chart

At this time, BioCryst Pharmaceuticals' Interest Income is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Ebit

Total Revenue

Total revenue comprises all receipts BioCryst Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioCryst Pharmaceuticals. It is also known as BioCryst Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from BioCryst Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Interest Income is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	327.6M	412.7M	430.5M	452.0M
Cost Of Revenue	7.3M	6.6M	4.7M	9.2M

Total Operating Expenses Cost Of Revenue

BioCryst Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Net Income	Income Tax Expense	Total Other Income Expense Net	Income Before Tax	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.56	0.59	0.56	0.56	0.6	-0.48	-0.58	-0.58	0.12	0.6	-0.65	0.05	-0.59	-0.63	0.61	0.54	-0.65	0.48	-0.12	0.34	-0.56	0.62
Interest Expense	0.56		0.98	0.99	0.99	0.97	-0.55	-0.64	-0.63	-0.04	0.97	-0.86	-0.48	-0.95	-0.9	0.94	0.7	-0.89	0.97	-0.43	0.69	-0.99	0.88
Selling General Administrative	0.59	0.98		0.97	0.97	0.98	-0.62	-0.7	-0.7	-0.04	0.98	-0.9	-0.41	-0.93	-0.93	0.94	0.65	-0.92	0.95	-0.45	0.75	-0.96	0.84
Total Revenue	0.56	0.99	0.97		1.0	0.96	-0.48	-0.57	-0.57	-0.03	0.96	-0.82	-0.51	-0.96	-0.86	0.91	0.7	-0.85	0.96	-0.4	0.71	-0.98	0.88
Gross Profit	0.56	0.99	0.97	1.0		0.95	-0.47	-0.57	-0.57	-0.03	0.95	-0.82	-0.51	-0.96	-0.86	0.91	0.7	-0.84	0.96	-0.4	0.72	-0.98	0.88
Other Operating Expenses	0.6	0.97	0.98	0.96	0.95		-0.72	-0.78	-0.78	-0.05	1.0	-0.94	-0.33	-0.89	-0.97	0.99	0.7	-0.95	0.95	-0.5	0.66	-0.96	0.83
Operating Income	-0.48	-0.55	-0.62	-0.48	-0.47	-0.72		0.96	0.96	0.08	-0.71	0.87	-0.2	0.37	0.84	-0.78	-0.45	0.83	-0.56	0.54	-0.26	0.54	-0.41
Ebit	-0.58	-0.64	-0.7	-0.57	-0.57	-0.78	0.96		1.0	0.1	-0.78	0.94	-0.21	0.53	0.91	-0.82	-0.57	0.89	-0.58	0.57	-0.45	0.6	-0.55
Ebitda	-0.58	-0.63	-0.7	-0.57	-0.57	-0.78	0.96	1.0		0.1	-0.78	0.93	-0.21	0.53	0.91	-0.82	-0.57	0.89	-0.58	0.58	-0.45	0.6	-0.54
Cost Of Revenue	0.12	-0.04	-0.04	-0.03	-0.03	-0.05	0.08	0.1	0.1		-0.05	0.06	0.05	0.0	0.06	-0.06	-0.01	0.07	-0.07	0.49	0.0	0.03	-0.05
Total Operating Expenses	0.6	0.97	0.98	0.96	0.95	1.0	-0.71	-0.78	-0.78	-0.05		-0.95	-0.33	-0.89	-0.97	0.99	0.7	-0.95	0.95	-0.5	0.66	-0.96	0.83
Net Income	-0.65	-0.86	-0.9	-0.82	-0.82	-0.94	0.87	0.94	0.93	0.06	-0.95		0.08	0.78	1.0	-0.96	-0.7	0.99	-0.81	0.54	-0.6	0.84	-0.76
Income Tax Expense	0.05	-0.48	-0.41	-0.51	-0.51	-0.33	-0.2	-0.21	-0.21	0.05	-0.33	0.08		0.45	0.14	-0.27	-0.12	0.18	-0.55	-0.1	-0.23	0.53	-0.44
Total Other Income Expense Net	-0.59	-0.95	-0.93	-0.96	-0.96	-0.89	0.37	0.53	0.53	0.0	-0.89	0.78	0.45		0.82	-0.82	-0.71	0.81	-0.86	0.32	-0.82	0.92	-0.9
Income Before Tax	-0.63	-0.9	-0.93	-0.86	-0.86	-0.97	0.84	0.91	0.91	0.06	-0.97	1.0	0.14	0.82		-0.97	-0.69	0.99	-0.85	0.53	-0.64	0.87	-0.77
Research Development	0.61	0.94	0.94	0.91	0.91	0.99	-0.78	-0.82	-0.82	-0.06	0.99	-0.96	-0.27	-0.82	-0.97		0.72	-0.95	0.93	-0.53	0.54	-0.93	0.79
Selling And Marketing Expenses	0.54	0.7	0.65	0.7	0.7	0.7	-0.45	-0.57	-0.57	-0.01	0.7	-0.7	-0.12	-0.71	-0.69	0.72		-0.64	0.63	-0.47	0.45	-0.71	0.85
Net Income From Continuing Ops	-0.65	-0.89	-0.92	-0.85	-0.84	-0.95	0.83	0.89	0.89	0.07	-0.95	0.99	0.18	0.81	0.99	-0.95	-0.64		-0.84	0.47	-0.65	0.87	-0.79
Non Operating Income Net Other	0.48	0.97	0.95	0.96	0.96	0.95	-0.56	-0.58	-0.58	-0.07	0.95	-0.81	-0.55	-0.86	-0.85	0.93	0.63	-0.84		-0.46	0.57	-0.98	0.8
Non Recurring	-0.12	-0.43	-0.45	-0.4	-0.4	-0.5	0.54	0.57	0.58	0.49	-0.5	0.54	-0.1	0.32	0.53	-0.53	-0.47	0.47	-0.46		-0.24	0.4	-0.34
Interest Income	0.34	0.69	0.75	0.71	0.72	0.66	-0.26	-0.45	-0.45	0.0	0.66	-0.6	-0.23	-0.82	-0.64	0.54	0.45	-0.65	0.57	-0.24		-0.63	0.66
Net Interest Income	-0.56	-0.99	-0.96	-0.98	-0.98	-0.96	0.54	0.6	0.6	0.03	-0.96	0.84	0.53	0.92	0.87	-0.93	-0.71	0.87	-0.98	0.4	-0.63		-0.89
Reconciled Depreciation	0.62	0.88	0.84	0.88	0.88	0.83	-0.41	-0.55	-0.54	-0.05	0.83	-0.76	-0.44	-0.9	-0.77	0.79	0.85	-0.79	0.8	-0.34	0.66	-0.89

Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.9M	748K	777K	1.4M	1.7M	1.0M
Interest Expense	11.9M	14.5M	59.3M	99.1M	108.2M	113.7M
Selling General Administrative	37.1M	61.4M	113.1M	144.5M	199.1M	209.1M
Total Revenue	48.8M	17.8M	157.2M	270.8M	331.4M	348.0M
Gross Profit	44.7M	16.1M	149.9M	264.2M	326.8M	343.1M
Other Operating Expenses	148.3M	192.6M	334.9M	419.3M	435.1M	456.9M
Operating Income	(99.5M)	(174.8M)	(177.7M)	(148.4M)	(103.7M)	(98.5M)
Ebit	(99.5M)	(168.3M)	(122.5M)	(145.3M)	(118.0M)	(112.1M)
Ebitda	(97.5M)	(167.6M)	(121.7M)	(143.9M)	(116.3M)	(110.5M)
Cost Of Revenue	4.1M	1.7M	7.3M	6.6M	4.7M	9.2M
Total Operating Expenses	144.2M	190.9M	327.6M	412.7M	430.5M	452.0M
Net Income	(120.1M)	(196.6M)	(184.1M)	(247.1M)	(226.5M)	(215.2M)
Income Tax Expense	11.2M	13.8M	2.3M	2.7M	310K	325.5K
Total Other Income Expense Net	(9.4M)	(8.1M)	(4.1M)	(95.9M)	(122.5M)	(128.6M)
Income Before Tax	(108.9M)	(182.8M)	(181.8M)	(244.4M)	(226.2M)	(237.5M)
Research Development	107.1M	123.0M	208.8M	253.3M	216.6M	227.4M
Net Income From Continuing Ops	(108.9M)	(192.2M)	(184.1M)	(247.1M)	(236.3M)	(224.5M)
Non Operating Income Net Other	2.1M	2.5M	(3.0M)	55.1M	63.4M	66.6M
Net Income Applicable To Common Shares	(108.9M)	(182.8M)	(184.1M)	(247.1M)	(222.4M)	(211.3M)
Non Recurring	560K	471K	375K	126K	113.4K	107.7K
Interest Income	1.9M	9.4M	62K	5.1M	14.0M	14.7M
Net Interest Income	(10.0M)	(5.1M)	(59.2M)	(94.0M)	(96.1M)	(91.3M)
Reconciled Depreciation	724K	748K	777K	1.4M	1.6M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Historical Income Statement

About BioCryst Income Statement Analysis

BioCryst Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

BioCryst Pharmaceuticals income statement Correlations

BioCryst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioCryst Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for BioCryst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Net Income
Total Revenue	+ 0.99	Interest Expense
Gross Profit	+ 0.99	Interest Expense

Net Interest Income	- 0.99	Interest Expense
Net Interest Income	- 0.98	Non Operating Income Net Other
Net Interest Income	- 0.98	Gross Profit
Net Interest Income	- 0.98	Total Revenue
Research Development	- 0.97	Income Before Tax
Income Before Tax	- 0.97	Total Operating Expenses